Literature DB >> 7856082

Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice.

S Abe1, Y Ota, S Koike, T Kurata, H Horie, T Nomura, S Hashizume, A Nomoto.   

Abstract

The transgenic mice, ICR-PVRTg21, carrying the human poliovirus receptor gene, were intraspinally inoculated with oral poliovirus vaccine viruses and the viruses that had been derived from a vaccine preparation by passagings at 38 degrees. Dose-dependent incidence of paralysis was observed in the transgenic mice inoculated with any of the viruses used. All transgenic mice showing histopathological lesions in the central nervous system appeared to display clinical signs that resembled those observed in human poliomyelitis. These suggest that relative neurovirulence levels of individual virus preparations can be estimated by values of 50% paralysis dose. Indeed, the parameter correlated well with monkey lesion scores of viruses used. Histopathological changes such as degeneration of neurons resemble those displayed by monkeys and were observed in the spinal cord, medulla oblongata, and pons. Thus, the transgenic mice, ICR-PVRTg21, may become a new animal model in place of monkeys for safety testing of oral poliovirus vaccine preparations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7856082     DOI: 10.1006/viro.1995.1030

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

Review 1.  Current status of poliovirus infections.

Authors:  J L Melnick
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

2.  Transgenic mouse model for the study of enterovirus 71 neuropathogenesis.

Authors:  Ken Fujii; Noriyo Nagata; Yuko Sato; Kien Chai Ong; Kum Thong Wong; Seiya Yamayoshi; Midori Shimanuki; Hiroshi Shitara; Choji Taya; Satoshi Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

3.  Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands.

Authors:  J H Reimerink; H G van der Avoort; A M van Loon; M P Koopmans
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

4.  Cell-dependent role for the poliovirus 3' noncoding region in positive-strand RNA synthesis.

Authors:  David M Brown; Steven E Kauder; Christopher T Cornell; Gwendolyn M Jang; Vincent R Racaniello; Bert L Semler
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene--influence of the transgene expression on pathogenesis.

Authors:  S Koike; C Taya; J Aoki; Y Matsuda; I Ise; H Takeda; T Matsuzaki; H Amanuma; H Yonekawa; A Nomoto
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Ayumi Imura; Yui Sudaka; Ayako Takashino; Kanami Tamura; Kyousuke Kobayashi; Noriyo Nagata; Hidekazu Nishimura; Katsumi Mizuta; Satoshi Koike
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

7.  Scavenger receptor b2 as a receptor for hand, foot, and mouth disease and severe neurological diseases.

Authors:  Seiya Yamayoshi; Ken Fujii; Satoshi Koike
Journal:  Front Microbiol       Date:  2012-02-06       Impact factor: 5.640

Review 8.  Molecular aspects of poliovirus pathogenesis.

Authors:  Akio Nomoto
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2007-12       Impact factor: 3.493

9.  An Insight into Recombination with Enterovirus Species C and Nucleotide G-480 Reversion from the Viewpoint of Neurovirulence of Vaccine-Derived Polioviruses.

Authors:  Yong Zhang; Dongmei Yan; Shuangli Zhu; Yorihiro Nishimura; Xufang Ye; Dongyan Wang; Jaume Jorba; Hui Zhu; Hongqiu An; Hiroyuki Shimizu; Olen Kew; Wenbo Xu
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

Review 10.  Macaque models of human infectious disease.

Authors:  Murray B Gardner; Paul A Luciw
Journal:  ILAR J       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.